Oral Micronized Progesterone Side Effects: Incidence Rates Across Trials

Oral micronized progesterone (OMP), sold in the United States under the brand name Prometrium, is bioidentical progesterone suspended in peanut oil and taken by mouth. It is FDA-approved for two indications: preventing endometrial hyperplasia in postmenopausal women taking estrogen, and treating secondary amenorrhea. Use for luteal-phase support in fertility treatment and for preterm birth prevention is off-label in the United States, even though it is common in practice and studied in trials.

Direct answer: The best-documented side effects of oral micronized progesterone are dose-dependent sedation (drowsiness, dizziness) and breast tenderness, both driven by progesterone's conversion to the neurosteroid allopregnanolone, which potentiates GABA-A receptors in the brain. These effects are common enough that bedtime dosing is standard practice specifically to convert sedation into a sleep aid rather than a daytime nuisance. Serious harms, clotting events, severe allergic reactions, liver injury, are uncommon, and observational (not randomized) comparative data suggest OMP has a more favorable metabolic and thrombotic profile than older synthetic progestins such as medroxyprogesterone acetate (MPA), though no large randomized trial has been powered to confirm a difference in hard cardiovascular or cancer outcomes between the two.

A note on the numbers in this article

Many pages on this topic cite precise incidence percentages (for example, "somnolence in 27% of patients") attached to a specific PMID or label page. Several of the citations commonly circulated for this topic do not reliably match the claim they are attached to when checked against the primary literature. Rather than repeat unverified numbers with false precision, this article states approximate ranges drawn from the general pattern reported across postmenopausal hormone therapy trials and the drug class literature, and flags where a reader or clinician should pull the primary trial or the current FDA label before relying on an exact figure for a clinical decision.

What is established, what is plausible, and what is not established

Established:

• OMP causes dose-dependent sedation and dizziness through allopregnanolone-mediated GABA-A potentiation. This mechanism is well described in pharmacology references and is the reason bedtime dosing is standard.
• OMP is contraindicated in peanut allergy because Prometrium capsules use a peanut oil vehicle.
• OMP undergoes extensive first-pass hepatic metabolism and is not recommended in active liver disease.
• Combining OMP with other CNS depressants (benzodiazepines, opioids, alcohol) produces additive sedation.

Plausible but not established by randomized outcome trials:

• That OMP carries meaningfully lower venous thromboembolism and breast cancer risk than synthetic progestins such as MPA. This is supported by observational cohort data and by mechanistic and metabolic differences (for example, favorable effects on HDL cholesterol and insulin sensitivity relative to MPA), but observational studies cannot rule out confounding by indication or by the type of woman who is prescribed OMP versus MPA. A 2025 claims-data analysis comparing oral estradiol plus micronized progesterone against conjugated estrogens plus medroxyprogesterone found differences in major adverse cardiovascular event risk between the two regimens, which is consistent with the hypothesis of a more favorable OMP profile, but claims-data analyses carry their own confounding limitations and should not be read as randomized trial evidence (Cirillo et al., 2025).
• That OMP tolerance (reduced sedation over weeks of use) is a real, reproducible phenomenon. This is widely reported in clinical experience but is not backed by a dedicated tolerance trial in the sources reviewed for this article.

Not established:

• A single, trial-confirmed sedation incidence percentage that applies across doses, populations, and regimens. Reported rates vary by dose (100 mg versus 200 mg versus 300 mg), by whether progesterone is combined with estrogen, and by how "somnolence" was defined and measured in a given trial. Any specific percentage should be checked against the trial or label it is attributed to before being used in patient counseling materials.
• Whether OMP shares the World Health Organization's International Agency for Research on Cancer classification of combined menopausal hormone therapy as a Group 1 carcinogen, which was based largely on trials and cohorts using synthetic progestins rather than OMP specifically.

The sedation and dizziness picture

Progesterone taken orally is extensively converted to allopregnanolone during first-pass liver metabolism, producing much higher levels of this neurosteroid than progesterone given vaginally or by injection. Allopregnanolone potentiates GABA-A receptors, the same receptor system targeted by benzodiazepines, which is why oral progesterone reliably produces sedation that other routes produce less of. Peak sedative effect generally occurs one to three hours after an oral dose, which is the pharmacological rationale for bedtime dosing rather than morning or midday dosing.

Higher doses (used for endometrial protection, typically 200 mg per day cyclically) are associated with more sedation than lower doses (used for luteal support, typically 100 mg per day). Women who need only a lower dose for a fertility indication generally report less daytime grogginess than women on a higher dose for endometrial protection, though a formal randomized head-to-head dose-comparison trial measuring this directly was not identified for this article and should be verified before being cited as a quantified difference.

Dizziness, unsteadiness, and headache are reported alongside somnolence in trial adverse-event tables for combined estrogen-progesterone regimens. In older women, sedation and dizziness translate into a real fall risk that clinicians should weigh, particularly when initiating therapy or increasing the dose.

Breast tenderness, bleeding, and endometrial protection

Breast tenderness is a commonly reported adverse event in trials of combined estrogen plus OMP regimens, typically most noticeable in the first few months and often easing with continued use. The mechanism is estrogen-driven ductal stimulation, only partly offset by progestogen opposition.

Cyclic OMP regimens (given roughly 12 to 14 days per month alongside estrogen) reliably produce a scheduled withdrawal bleed in most women during the first year, along with a meaningful rate of unscheduled spotting that tends to decline over successive cycles as the endometrium responds to sustained hormone exposure. Continuous combined regimens (daily low-dose OMP with daily estrogen) tend to produce less predictable scheduled bleeding but more early unpredictable spotting.

The core endometrial-safety finding that supports OMP's role in menopausal hormone therapy is that adequate progestogen, including micronized progesterone at labeled doses, prevents the endometrial hyperplasia that unopposed estrogen produces in women with a uterus. This is a foundational, well-replicated finding in the menopausal hormone therapy literature and is the basis for the FDA labeling requirement that women with an intact uterus receive progestogen opposition alongside estrogen.

Cardiovascular, metabolic, and cancer risk: what differs from synthetic progestins, and what remains unresolved

Most of what clinicians know about menopausal hormone therapy and cardiovascular or breast cancer risk comes from trials and cohorts that used medroxyprogesterone acetate, not oral micronized progesterone. That distinction matters and is frequently blurred in popular summaries. A useful question is not "does hormone therapy raise cardiovascular or breast cancer risk" but "does the specific progestogen used change that risk," and the honest answer is that OMP and MPA are not interchangeable in the observational and mechanistic data, even though they have not been compared head-to-head in a cardiovascular or cancer-outcome randomized trial of adequate size.

A 2025 narrative review of cardiovascular risk in menopause and menopausal hormone therapy discusses how progestogen choice, route, and timing of initiation ("timing hypothesis") all modify cardiovascular risk estimates, and it is a reasonable current reference for clinicians trying to reconcile older large-trial data (which used MPA) with newer, more granular regimen-specific data (review, 2025). The 2025 claims-data comparison of oral estradiol plus micronized progesterone versus conjugated estrogens plus medroxyprogesterone acetate is one of the more direct real-world comparisons available for major adverse cardiovascular events, and readers or clinicians wanting a current, regimen-specific risk estimate should read that paper directly rather than rely on a percentage repeated secondhand (claims analysis, 2025).

Metabolically, oral micronized progesterone is generally reported not to worsen insulin sensitivity or blunt estrogen's favorable effect on HDL cholesterol the way medroxyprogesterone acetate does in some trial data. This is a plausible reason a clinician might prefer OMP for a patient with prediabetes or dyslipidemia, but it is a surrogate-marker difference, not a demonstrated difference in heart attack or stroke rates.

Allergic reactions and the peanut oil vehicle

Prometrium capsules are formulated in peanut oil to aid absorption. Women with a known peanut allergy should not take oral Prometrium capsules; this is a labeled contraindication, not a theoretical concern. Patients who need progesterone but have a peanut allergy have alternative delivery options to discuss with a prescriber, including vaginal progesterone preparations and progestin-containing intrauterine devices for endometrial protection (the IUD delivers a different progestin, levonorgestrel, not progesterone itself).

Separately, a small number of women experience autoimmune progesterone dermatitis, a rare hypersensitivity reaction to endogenous or exogenous progesterone causing cyclic hives, eczema, or rarely more severe allergic reactions. This condition is uncommon and is not well quantified in incidence terms; a patient with cyclic allergic symptoms tied to the menstrual cycle or to starting progesterone therapy should be evaluated rather than assume the diagnosis from a general article.

Mood effects and who may be more sensitive

Allopregnanolone's effect on mood is not uniformly calming. Most users report neutral-to-positive effects on sleep and anxiety, but some women, particularly those with a history of premenstrual dysphoric disorder (PMDD) or severe premenstrual syndrome, may have an atypical or negative behavioral response to allopregnanolone exposure rather than the sedative-calming response seen in most people. This is a recognized pattern in the neurosteroid literature and is a reasonable basis for asking about PMDD history before starting oral progesterone, though it does not mean every woman with a PMDD history will react badly.

Depression and mood-related adverse events appear among spontaneous reports submitted to the FDA's Adverse Event Reporting System (FAERS) for Prometrium. FAERS is a passive reporting system: reports are voluntary, there is no reliable denominator of total users, and a report does not establish that the drug caused the event. FAERS is useful for signal detection, not for calculating an incidence rate, and should be described that way rather than turned into a percentage.

Use in pregnancy and luteal-phase support

Oral and vaginal progesterone are both used off-label to support pregnancy, including for luteal-phase support after fertility treatment and to reduce preterm birth risk in some high-risk pregnancies. Vaginal progesterone has more trial evidence behind it for preterm birth prevention than oral progesterone does, and oral dosing raises allopregnanolone levels more than vaginal dosing, which brings theoretical (not conclusively resolved) questions about fetal exposure to a sedative neurosteroid. A registered randomized trial protocol comparing oral dydrogesterone against oral micronized progesterone for threatened miscarriage was published in 2025; as a protocol paper it describes planned methodology rather than results, so it should not be cited as evidence of a safety or efficacy difference until the trial reports outcomes (trial protocol, 2025).

Anyone considering oral or vaginal progesterone during pregnancy should discuss the specific indication, dose, and route with their obstetric clinician rather than extrapolate from general menopausal hormone therapy data, since the populations, doses, and risk-benefit calculus differ substantially.

Drug interactions that change the side-effect picture

Progesterone is metabolized mainly through CYP3A4, with a secondary role for CYP1A2. Strong CYP3A4 inhibitors (for example, certain antifungal or antiviral medications) can raise progesterone levels and intensify sedation and other dose-related effects. Strong CYP3A4 inducers (for example, rifampin or carbamazepine) can lower progesterone exposure, which matters most for indications like endometrial protection where a minimum exposure level is needed for efficacy. Separately, and regardless of CYP status, combining oral progesterone with other sedating medications (benzodiazepines, opioids, sedating antihistamines, alcohol) produces additive drowsiness through simple pharmacodynamic overlap, not a metabolic interaction.

Older adults and fall risk

Sedation and dizziness carry more consequence in women over 65, where a fall can mean a fracture. This is a reason some clinicians start at a lower dose in older patients and monitor closely rather than begin at a standard postmenopausal dose. Any decision to start, continue, or stop hormone therapy in an older adult should weigh this sedation and fall-risk profile alongside the broader, well-established cautions around hormone therapy and age at initiation, and should be made with a clinician who knows the patient's full history.

When to seek urgent care rather than wait it out

If you experience sudden leg swelling or pain, chest pain, sudden shortness of breath, sudden severe headache, vision changes, or signs of a severe allergic reaction (difficulty breathing, swelling of the face or throat, widespread hives) after beginning oral micronized progesterone, seek immediate medical attention rather than monitoring at home, even though these events are uncommon in large population studies.

Decision guide: what changes the risk-benefit calculus for oral micronized progesterone

This is not a substitute for an individualized medical decision. It is a structured way to think through the factors that most often change whether OMP, a dose adjustment, or an alternative progestogen delivery is the more sensible discussion to have with a prescriber.

Common questions

What are the most common side effects of oral micronized progesterone? Sedation-type effects (drowsiness, dizziness) and breast tenderness are the most consistently reported adverse events across trials of oral micronized progesterone, alongside bleeding irregularities in cyclic regimens. Exact percentages vary meaningfully by dose, regimen, and trial definition, so a single number should not be treated as universal.

Why does oral micronized progesterone cause drowsiness? Oral progesterone is extensively converted to allopregnanolone, a neurosteroid that potentiates GABA-A receptors in the brain, the same receptor system targeted by benzodiazepines. This effect is dose-dependent and peaks a few hours after a dose, which is why bedtime dosing is standard practice.

Is oral micronized progesterone safer than synthetic progestins like MPA? Observational cohort data and metabolic surrogate markers suggest a more favorable thrombotic, breast-cancer, and lipid profile for OMP compared with medroxyprogesterone acetate, and a 2025 claims-data comparison of regimen-level cardiovascular outcomes adds real-world evidence in the same direction. No adequately powered randomized trial has directly compared hard cardiovascular or cancer outcomes between the two progestogens, so "safer" should be understood as a plausible, evidence-supported hypothesis rather than a settled fact.

Is oral micronized progesterone safe with a peanut allergy? No. Prometrium capsules use a peanut oil vehicle and are contraindicated in people with a diagnosed peanut allergy. Non-oral progesterone formulations or other endometrial-protection options should be discussed instead.

Can oral micronized progesterone affect mood? Most users report a calming or sleep-promoting effect, but people with a history of premenstrual dysphoric disorder may have an atypical response to allopregnanolone. Mood changes, including depression, appear among reports submitted to the FDA's passive adverse event reporting system, which can detect a signal but cannot establish how common the effect truly is or that the drug caused it.

References

• Kling JM, et al. Cardiovascular Risk Associated with Menopause and Menopause Hormone Therapy: A Review and Contemporary Approach to Risk Assessment (2025). https://pubmed.ncbi.nlm.nih.gov/41066010/
• Cirillo DJ, et al. Major adverse cardiovascular events risk in menopausal women treated with oral estradiol/micronized progesterone versus conjugated estrogens/medroxyprogesterone: a claims data analysis in the USA (2025). https://pubmed.ncbi.nlm.nih.gov/40773298/
• Oral dydrogesterone versus oral micronized progesterone in threatened miscarriage: protocol paper for a randomized controlled trial (2025). https://pubmed.ncbi.nlm.nih.gov/39831807/
• U.S. Food and Drug Administration. FDA Adverse Event Reporting System (FAERS) Public Dashboard. https://www.fda.gov/drugs/questions-and-answers-fdas-adverse-event-reporting-system-faers/fda-adverse-event-reporting-system-faers-public-dashboard

This article is pending qualified clinical review. Specific incidence figures, dosing comparisons, and the exact current FDA prescribing information for Prometrium should be verified against the primary label and trial publications before use in patient counseling or clinical decision-making. It does not provide individualized diagnosis or dosing advice; discuss your specific history and medications with a qualified clinician.